tbuckley/cabot-search huggingface dataset:
Outcome of (Novel) Subgroups in 1257 Pediatric Patients with KMT2A-Rearranged Acute Myeloid Leukemia (AML) and the Significance of Minimal Residual Disease (MRD) Status: A Retrospective Study By the I-BFM-SG
Authors: Romy E. Van Weelderen, Kim Klein, Bianca F. Goemans, Christian M. Zwaan, Hester A. De Groot-Kruseman, Jonas Abrahamsson, Nira Arad-Cohen, Emmanuelle Bart-Delabesse, Barbara Buldini, Barbara De Moerloose, Michael Dworzak, Sarah Elitzur, José M. Fernández Navarro, Robert B. Gerbing, Erin Guest, Shau-Yin Ha, Christine J. Harrison, Henrik Hasle, Kathy Jackson, Charikleia Kelaidi, Hélène Lapillonne, Guy Leverger, Franco Locatelli, Takako Miyamura, Sophia Polychronopoulou, Mareike Rasche, Jeffrey E. Rubnitz, Jan Stary, Daisuke Tomizawa, Femke Verwer, Gertjan J.L. Kaspers
Journal: Blood (2020)
The Direct Interactions with Bone Marrow Microenvironment Confer Resistance to the Inhibition of Oxidative Phosphorylation in AML
Authors: Yoko Tabe, Kaori Saito, Kotoko Yamatani, Haeun Yang, Rodrigo Jacamo, Helen Ma, Vivian Ruvolo, Qi Zhang, Vinitha Mary Kuruvilla, Natalia Baran, Junichi Imoto, Kazuho Ikeo, Koya Suzuki, Takashi Miida, Michael Andreeff, Christopher P Vellano, Joseph R Marszalek, Marina Konopleva
Journal: Blood (2020)
AB0017 CONSTANT GENETIC MARKER IL1B T-31С IS ASSOCIATED WITH ANAMNESIS OF BIOLOGICAL DRUGS TREATMENT IN RHEUMATOID ARTHRITIS
Authors: V. Omelchenko, E. Letyagina, Y. Kurochkina, A. Akimova, A. Shevchenko, M. Korolev
Journal: Annals of the Rheumatic Diseases (2020)

Background: Rheumatoid arthritis (RA) is chronic progressive joint disease with erosions formation. Timely and effectiveness treatment is important due to quickly structural damage and progressive losing of active motion. Synthetic DMARDs didn’t have a sufficient effect. Using biological drugs seemed like a panacea, but according to investigations at least 30-40% RA-patients lost treatment efficiency. Biological drugs act through immune cascade, that’s why mutation in regulatory region of cytokine genes may partly determine treatment failure. Objectives: The objective of our study was to analyze the frequency of IL1 T-31C single nucleotide polymorphism in patient with rheumatoid arthritis and its association with biological drugs prescribing. Methods: One hundred two Caucasian RA-patients (age – 56 yrs [45; 61]; DAS28 4.7 [3.8; 5.9]) were enrolled in our study. All of them had American College of Rheumatology (ACR)-defined RA (1987 classification criteria) and gave written inform consent. Single nucleotide polymorphisms IL1B T-31C (rs1143627), IL4 C-590T (rs2243250), IL10 C-592A (rs1800872), IL10 A-1082G (rs1800896) were determined by restriction fragment length polymorphism. Descriptive statistics, Chi-squared test were used for data analysis. Results are presented as median and 25th/75th percentiles (Me [25th percentile; 75th percentile]). Results: The most of SNPs analyzed had corresponded to the Hardy Weinberg equilibrium (HWE). The only exception was IL1B T-31C – the frequencies were differed statistically significant from HWE (p=0,03). Forty seven (46.1%) patients were treatment with biological drugs. Homozygotes IL1b -31CС were founded more frequently beside patients with biological treatment compare with other group (13 from 47 (27,7%) vs. 6 from 52 (11.5%), p=0,042). Other SNPs didn’t demonstrate any associations. Conclusion: Single nucleotide polymorphism IL1B T-31C (rs1143627) may be used for prognosis of basic anti-inflammatory therapy inefficiency and the needing for prescribing biological therapy. Disclosure of Interests: None declared
Impact of Molecular Response at Specific Timepoints in Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Second Generation Tyrosine Kinase Inhibitors
Authors: Koji Sasaki, Hagop M. Kantarjian, Ghayas C. Issa, Guillermo Garcia-Manero, Tapan M. Kadia, William G. Wierda, Musa Yilmaz, Courtney D. DiNardo, Jeffrey Skinner, Rita Khouri, Naveen Pemmaraju, Patrice Nasnas, Sara E Dellasala, Sherry A. Pierce, Jorge E. Cortes, Elias Jabbour
Journal: Blood (2020)
Eosinophilic pulmonary vasculitis as a manifestation of the hyperinflammatory phase of COVID-19
Authors: Eva Luecke, Andreas Jeron, Andrea Kroeger, Dunja Bruder, Sabine Stegemann-Koniszewski, Doerthe Jechorek, Katrin Borucki, Dirk Reinhold, Annegret Reinhold, Sebastian Foellner, Thorsten Walles, Thomas Hachenberg, Jens Schreiber
Journal: Journal of Allergy and Clinical Immunology (2020)
Cael-101 Is Well-Tolerated in AL Amyloidosis Patients Receiving Concomitant Cyclophosphamide-Bortezomib-Dexamethasone (CyborD): A Phase 2 Dose-Finding Study (NCT04304144)
Authors: Jason Valent, John Silowsky, Michael R. Kurman, Eileen Daniel, Janet Jobes, Mark Harnett, Margaret Ziola, Jessica Roviwong, Sherry Fada, Michael Spector, Susan B. Sobolov
Journal: Blood (2020)
Critical requirement for BCR, BAFF, and BAFFR in memory B cell survival
Authors: Jennifer Müller-Winkler, Richard Mitter, Julie C.F. Rappe, Lesley Vanes, Edina Schweighoffer, Hamid Mohammadi, Andreas Wack, Victor L.J. Tybulewicz
Journal: The Journal of Experimental Medicine (2020)

Memory B cells (MBCs) are long-lived cells that form a critical part of immunological memory, providing rapid antibody responses to recurring infections. However, very little is known about signals controlling MBC survival. Previous work has shown that antigen is not required for MBC survival, but a requirement for the B cell antigen receptor (BCR) has not been tested. Other studies have shown that, unlike naive B cells, MBCs do not express BAFFR and their survival is independent of BAFF, the ligand for BAFFR. Here, using inducible genetic ablation, we show that survival of MBCs is critically dependent on the BCR and on signaling through the associated CD79A protein. Unexpectedly, we found that MBCs express BAFFR and that their survival requires BAFF and BAFFR; hence, loss of BAFF or BAFFR impairs recall responses. Finally, we show that MBC survival requires IKK2, a kinase that transduces BAFFR signals. Thus, MBC survival is critically dependent on signaling from BCR and BAFFR.
Assessment of Tumor Lysis Syndrome in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax in the Clinical Trial and Post-Marketing Settings
Authors: John F. Seymour, John G. Gribben, Matthew S. Davids, Anthony Mato, Jeff P Sharman, Aimee Cyr, Cynthia Bartkus, German Pena, Michelle Boyer, Simon Sharmokh, Tanya S Rosenberg, William G. Wierda
Journal: Blood (2020)
The Application of Machine Learning to Improve the Subclassification and Prognostication of Acute Myeloid Leukemia
Authors: Hassan Awada, Arda Durmaz, Carmel Gurnari, Ashwin Kishtagari, Manja Meggendorfer, Cassandra M. Kerr, Teodora Kuzmanovic, Jibran Durrani, Yasunobu Nagata, Tomas Radivoyevitch, Anjali S Advani, Farhad Ravandi, Hetty E. Carraway, Aziz Nazha, Claudia Haferlach, Yogenthiran Saunthararajah, Jacob Scott, Valeria Visconte, Hagop M. Kantarjian, Tapan M. Kadia, Mikkael A. Sekeres, Torsten Haferlach, Jaroslaw P. Maciejewski
Journal: Blood (2020)
<i>TRAF3</i> Loss Drives Alternative NF-κB Pathway Activation in Diffuse Large B-Cell Lymphoma
Authors: Michael Y. Li, Lauren C. Chong, Elizabeth Chavez, Bruce W Woolcock, Adele Telenius, Vivian Lam, Gerald Krystal, David W. Scott, Elena Viganò, Shannon Healy, Christian Steidl
Journal: Blood (2020)
Relationship of Area-Level Socioeconomic Status Indicators and Nutritional Anemias: Analysis of Folate, Vitamin B12, and Iron Deficiencies
Authors: Miguel Gonzalez Velez, Carolyn Mead-Harvey, Heidi E. Kosiorek, Yael Kusne, Leyla Bojanini, Candido E. Rivera, Donald Northfelt, Chung-II Wi, Leslie Padrnos
Journal: Blood (2020)
The Genomic Landscape of <i>Wilms' Tumor 1</i> (<i>WT1</i>) Mutant Acute Myeloid Leukemia
Authors: Hassan Awada, Arda Durmaz, Carmelo Gurnari, Misam Zawit, Sunisa Kongkiatkamon, Simona Pagliuca, Cassandra M. Kerr, Hetty E. Carraway, Aziz Nazha, Mikkael A. Sekeres, Jaroslaw P. Maciejewski, Valeria Visconte
Journal: Blood (2020)
Risk of Serious Infections with Lenalidomide Based Regimens in Multiple Myeloma: A Network Meta-Analysis
Authors: Nayab Mirza, Anum Javaid, Muhammad Ashar Ali, Wajeeha Aiman, Muhammad Yasir Anwar, Farwah N. Fatima, Rimsha Ali, Aqsa Mumtaz, Sana Khan, Faiz Anwer
Journal: Blood (2020)
Brentuximab Vedotin As Single Agent in the Treatment of Relapsed/Refractory CD30 Positive Peripheral T-Cell Lymphoma Patients: A Phase 2 Study of the Fondazione Italiana Linfomi
Authors: Vittorio Stefoni, Paolo Corradini, Lorella Orsucci, Stefano Volpetti, Lisa Argnani, Anna Dodero, Cinzia Pellegrini, Pier Luigi Zinzani
Journal: Blood (2020)
A SARS-CoV-2 Outbreak Illustrating the Challenges in Limiting the Spread of the Virus — Hopi Tribe, May–June 2020
Authors: Jocelyn Hirschman, Harpriya Kaur, Kay Honanie, Royce Jenkins, Duane A. Humeyestewa, Rachel M. Burke, Tracy M. Billy, Oren Mayer, Mose Herne, Mark Anderson, Ravikiran Bhairavabhotla, Graydon Yatabe, S. Arunmozhi Balajee
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

On June 3, 2020, a woman aged 73 years (patient A) with symptoms consistent with coronavirus disease 2019 (COVID-19) (1) was evaluated at the emergency department of the Hopi Health Care Center (HHCC, an Indian Health Services facility) and received a positive test result for SARS-CoV-2, the virus that causes COVID-19.The patient's symptoms commenced on May 27, and a sibling (patient B) of the patient experienced symptom onset the following day.On May 23, both patients had driven together and spent time in a retail store in Flagstaff, Arizona.Because of their similar exposures, symptom onset dates, and overlapping close contacts, these patients are referred to as co-index patients.The co-index patients had a total of 58 primary (i.e., direct) and secondary contacts (i.e., contacts of a primary contact); among these, 27 (47%) received positive SARS-CoV-2 test results.Four (15%) of the 27 contacts who became ill were household members of co-index patient B, 14 (52%) had attended family gatherings, one was a child who might have transmitted SARS-CoV-2 to six contacts, and eight (30%) were community members.Findings from the outbreak investigation prompted the HHCC and Hopi Tribe leadership to strengthen community education through community health representatives, public health nurses, and radio campaigns.In communities with similar extended family interaction, emphasizing safe ways to stay in touch, along with wearing a mask, frequent hand washing, and physical distancing might help limit the spread of disease.The Hopi are a Native American tribe and a sovereign nation, primarily residing on the 1.5 million-acre Hopi Reservation in northeastern Arizona (2).The Hopi Tribe leadership declared a COVID-19-associated state of emergency on March 17, which was followed by a stay-at-home order March 23 (with projected reopening on June 20).On April 13, HHCC reported its first laboratory-confirmed COVID-19 case in a patient residing on the Hopi Reservation, and cases continued to be diagnosed at low levels through May.However, at the beginning of June, HHCC reported that during the preceding 14 days, the number of new cases had increased sharply, from 1-2 to 10-15 per day (J Hirschman, MD, CDC, personal communication, June 2020).
Targeting Glycosylated Ptgds Displays Anti-Tumor Activities in Diffuse Large B-Cell Lymphoma through Down-Regulation of Wnt Pathway
Authors: Shunfeng Hu, Xiangxiang Zhou, Juan Yang, Shuai Ren, Yiqing Cai, Yang Han, Jiarui Liu, Yi Zhao, Xin Wang
Journal: Blood (2020)
Real-World Data with the Use of Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
Authors: M Moraima Jimenez, Sabela Bobillo, Ana Pérez, Pamela Arenas, Alba Cabirta, Eva Catala, Yva Rodriguez, Lucia Martin, Angel Serna, Francesc Bosch, David Valcárcel
Journal: Blood (2020)
An Integrative Unbiased Global Analysis of the Metabolic Adaptive Response to Tryptophan Deprivation in Classical Hodgkin Lymphoma
Authors: Fabrizio Puglisi, Enrico La Spina, Alessandro Barbato, Grazia Scandura, Cesarina Giallongo, Daniele Tibullo, Francesco Di Raimondo, Alessandra Romano
Journal: Blood (2020)
Direct Oral Anticoagulants for Myeloproliferative Neoplasms (MPN-DOACs): Results from an International Study on 442 Patients
Authors: Tiziano Barbui, Valerio De Stefano, Alessandra Carobbio, Alessandra Iurlo, Alberto Alvarez-Larran, Alessandro M. Vannucchi, Francesca Palandri, Claire Harrison, Hassan Sibai, Martin Griesshammer, Massimiliano Bonifacio, Elena M Elli, Chiara Trotti, Steffen Koschmieder, Giuseppe Carli, Giulia Benevolo, Jean-Christophe Ianotto, Swati Goel, Anna Falanga, Silvia Betti, Daniele Cattaneo, Eduardo Arellano-Rodrigo, Lara Mannelli, Nicola Vianelli, Andrew Doyle, Vikas Gupta, Kai Wille, Douglas Tremblay, John Mascarenhas
Journal: Blood (2020)
Abstract 492: Dual Stem Cell Therapy Improves the Cardiac Function After Experimental Myocardial Infarction
Authors: Sinziana Popescu, Ana-Mihaela Lupan, Preda Bogdan Mihai, Maya Simionescu, Alexandrina Burlacu
Journal: Circulation Research (2020)

As the mortality associated with cardiovascular diseases has accelerated in the past 10 years, advances in treatment options can have significant impact on the global population health. Mesenchymal Stromal Cells (MSC) have shown limited efficacy in clinical trials as sole contributors to tissue regeneration. Thus, we questioned whether the presence of Endothelial Colony Forming Cells (ECFC) could improve MSC-based cellular therapy of the infarcted myocardium. Acute myocardial infarction was induced in immunodeficient NSG mice by left coronary artery ligation and then MSCs or MSCs+ECFCs were immediately injected in the ventricular wall. Both healthy and sham-treated infarcted mice served as controls. At 7 days post-transplantation, echocardiography, qPCR and Western Blot (WB) were performed to assess cardiac function and protein expression. MSC - ECFC reciprocal modulation was studied in vitro by 24-hour co-culture in dual-chamber system or in direct contact, followed by qPCR and WB. The secretome collected from cultures was characterized by Matrigel angiogenesis assay, Proteome Profiler Arrays and ELISA. The results revealed that in dual-cell transplant compared to single transplant group the cardiac function (ejection fraction and stroke volume) was significantly improved. The protein expression of junctional molecules such as Connexin 43 and Integrin α-5 was increased by more than twofold in the MSC+ECFC vs. MSC-only group. Moreover, both MSC and ECFC secreted high levels of pro-angiogenic molecules, with only partially overlapping profiles, capable of inducing tube-like vascular structures on Matrigel. These observations suggest a putative complementary contribution of MSC and ECFC to the cardiac repair process. Significant increase in the Integrin α-5 expression was achieved in both culture settings, indicating a mechanism independent of cell to cell contact. However, a synergistic paracrine effect of the MSC-ECFC pair only occured after close cell interaction, especially for VEGF, SDF-1 and YKL-40, thus suggesting that both cell types are needed for sustained effects. In conclusion, we provide evidence that the complementary, dual stem cell-based therapy could positively modulate the function of infarcted myocardium.
Throly Score Successfully Classifies Hodgkin Lymphoma Patients at Risk of Thromboembolic Complication
Authors: Darko Antic, Vladimir Otasevic, Sven Borchmann, Horst Muller, Vojin Vukovic, Vladislava Djurasinovic, Kristina Tomic, Biljana Mihaljevic, Grigoris Gerotziafas, Andreas Engert, Jawed Fareed
Journal: Blood (2020)
Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Results of a Lysa Multicenter, Phase II Study. "the TOTAL Trial"
Authors: Olivier Tournilhac, Maya Hacini, Kamal Bouabdallah, Kamel Laribi, Marie Maerevoet, Loic Ysebaert, Stephanie Guidez, Steven Le Gouill, Marc André, Jehan Dupuis, Catherine Thieblemont, Emmanuel Bachy, Nicolas Daguindau, Franck Morschhauser, Sabine Tricot, Pierre Feugier, Anne Banos, Thierry Lamy De La Chapelle, Adrien Chauchet, Emmanuel Gyan, Guillaume Cartron, Hassan Farhat, Vincent Camus, Bernard Drenou, Hacene Zerazhi, David Sibon, Emmanuelle Nicolas-Virelizier, Caroline Delette, Sylvia Snauwaert, Nicole Straetmans, Richard Delarue, Marie Parrens, Céline Bossard, Laurence De Leval, Philippe Gaulard, Gandhi Laurent Damaj
Journal: Blood (2020)
A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102
Authors: Ryotaro Nakamura, Wael Saber, Michael J Martens, Alyssa Ramirez, Bart L. Scott, Betul Oran, Eric Leifer, Roni Tamari, Asmita Mishra, Richard T. Maziarz, Joseph P. McGuirk, Peter Westervelt, Sumithra Vasu, Mrinal M. Patnaik, Rammurti Kamble, Stephen J. Forman, Mikkael A. Sekeres, Frederick R. Appelbaum, Adam M. Mendizabal, Brent Logan, Mary M. Horowitz, Corey Cutler
Journal: Blood (2020)
Tissue-resident CD8 <sup>+</sup> T cells drive age-associated chronic lung sequelae after viral pneumonia
Authors: Nick P. Goplen, Yue Wu, Young Min Son, Chaofan Li, Zheng Wang, In Su Cheon, Li Jiang, Bibo Zhu, Katayoun Ayasoufi, Eduardo N. Chini, Aaron J. Johnson, Robert Vassallo, Andrew H. Limper, Nu Zhang, Jie Sun
Journal: Science Immunology (2020)

Lower respiratory viral infections, such as influenza virus and severe acute respiratory syndrome coronavirus 2 infections, often cause severe viral pneumonia in aged individuals. Here, we report that influenza viral pneumonia leads to chronic nonresolving lung pathology and exacerbated accumulation of CD8+ tissue-resident memory T cells (TRM) in the respiratory tract of aged hosts. TRM cell accumulation relies on elevated TGF-β present in aged tissues. Further, we show that TRM cells isolated from aged lungs lack a subpopulation characterized by expression of molecules involved in TCR signaling and effector function. Consequently, TRM cells from aged lungs were insufficient to provide heterologous protective immunity. The depletion of CD8+ TRM cells dampens persistent chronic lung inflammation and ameliorates tissue fibrosis in aged, but not young, animals. Collectively, our data demonstrate that age-associated TRM cell malfunction supports chronic lung inflammatory and fibrotic sequelae after viral pneumonia.
Targeting Antibody Checkpoint Fcgriib Using Monoclonal Antibody BI-1206 to Overcome Therapeutic Resistance in Mantle Cell Lymphoma
Authors: Alexa A Jordan, Joseph McIntosh, Yang Liu, Angela Leeming, William Lee, Ingrid Karlsson, Linda Mårtensson, Mathilda Kovacek, Ingrid Teige, Björn Frendéus, Michael Wang, Changying Changying Jiang
Journal: Blood (2020)
Neutralization of S100A4 induces stabilization of atherosclerotic plaques: role of smooth muscle cells
Authors: Antonija Sakic, Chiraz Chaabane, Noona Ambartsumian, Jörg Klingelhöfer, Sylvain Lemeille, Brenda R Kwak, Mariam Grigorian, Marie-Luce Bochaton-Piallat
Journal: Cardiovascular Research (2020)

During atherosclerosis, smooth muscle cells (SMCs) accumulate in the intima where they switch from a contractile to a synthetic phenotype. From porcine coronary artery, we isolated spindle-shaped (S) SMCs exhibiting features of the contractile phenotype and rhomboid (R) SMCs typical of the synthetic phenotype. S100A4 was identified as a marker of R-SMCs in vitro and intimal SMCs, in pig and man. S100A4 exhibits intra- and extracellular functions. In this study, we investigated the role of extracellular S100A4 in SMC phenotypic transition.
Silencing of CD24 affects some progression-associated genes in human glioblastoma cells.
Authors: Tsuyoshi Fukushima, Makiko Kawaguchi, Nobuyasu Takahashi, Hiroyuki Tanaka, Hiroshi Itoh, Hiroaki Kataoka
Journal: Cancer Research (2008)

310  Glioblastoma is the most frequent malignant brain tumor characterized by rapid growth, extensive invasiveness, and angiogenesis. The prognosis of patients with glioblastoma remains extremely poor because of not only tumor location but also its malignant biological features and resistance to therapeutic modalities. In a previous study, we have identified CD24 as a candidate for the progression associated genes in glioblastoma cells (Abstract number 304, 97th Annual meeting 2006 of AACR). CD24 is a small glycoprotein linked to the plasma membrane by a glycosylphosphatidylinositol lipid anchor, and has been implicated in the invasiveness and metastasizing capability of various cancers such as lung, breast, ovary, prostate, pancreas, and colorectal cancers. Reverse transcription PCR (RT-PCR) revealed some glioblastoma specimens and cell lines overexpressed CD24 mRNA. We used short hairpin RNA (shRNA) expression retroviral vector to inactivate CD24 gene of U251 and YKG-1 human glioblastoma cell lines overexpressing CD24. We also performed engineered overexpression of CD24 in U87, A172, and KS-1, human glioblastoma cell lines with low endogenous CD24. Stable knockdown of CD24 resulted in decreased invasiveness of glioblastoma cells, and overexpression of CD24 enhanced the invasion in in vitro matrigel invasion assays. Engineered CD24 overexpression also enhanced invasive growth of U87 in in vivo intracerebral transplantation model using nude mice. The cDNA microarrays for transcriptional profiling revealed significantly reduced expression of some progression associated genes in response to CD24 knockdown in both U251 and YKG-1. The representative genes are as follows; c-Met, metastasis-associated lung adenocarcinoma transcript-1 (MALAT-1), ADAM10, eukaryotic translation initiation factor 4E (eIF4E), and Ras-related protein Rab-23. We analyzed the synergic or linked expression of these genes to CD24 using RT-PCR and real-time RT-PCR. These results indicate that CD24 may have a role in malignant phenotype of glioblastoma cells, and thus serve as a potential therapeutic target in glioblastoma.
Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2)
Authors: David Spigel, Robert Jotte, John Nemunaitis, Merrill Shum, Jeffrey Schneider, Jerome Goldschmidt, Jennifer Eisenstein, David Berz, Lasika Seneviratne, Matei Socoteanu, Viralkumar Bhanderi, Kartik Konduri, Meng Xia, Hong Wang, Rebecca R. Hozak, Ivelina Gueorguieva, David Ferry, Leena Gandhi, Bo H. Chao, Igor Rybkin
Journal: Journal of Thoracic Oncology (2020)
Baseline Mutations Lack Impact on Clinical Outcomes and Molecular Response in Core Binding Factor Leukemia Treated with Highly Effective Regimen
Authors: Gautam Borthakur, Tapan M. Kadia, Guillermo Garcia-Manero, Naveen Pemmaraju, Naval Daver, Courtney D. DiNardo, Koichi Takahashi, Elias Jabbour, Maro Ohanian, Guillermo Montalban Bravo, Farhad Ravandi, Hagop M. Kantarjian, Keyur P. Patel, Mark Brandt
Journal: Blood (2020)
Recil 2017 Criteria Demonstrated Similar Prognostic Value and Detected a Comparable Treatment Difference between Obinutuzumab- and Rituximab-Chemotherapy Compared with Cheson 2007 and Lugano 2014 Criteria in Patients with Previously Untreated Advanced-Stage Follicular Lymphoma
Authors: Lale Kostakoglu, Andrew Davies, Michael Herold, Wolfgang Hiddemann, Robert Marcus, Judith Trotman, Andrea Knapp, Federico Mattiello, Tina G Nielsen, Deniz Sahin, Carol Ward, Anas Younes
Journal: Blood (2020)
BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Predictor for Treatment-Free Remission Failure
Authors: Dennis Dong Hwan Kim, Igor Nicolas Novitzky-Basso, Taehyung Kim, Eshetu G Atenafu, Donna L. Forrest, Lynn Savoie, Isabelle Bence-Bruckler, Mary-Margaret Keating, Lambert Busque, Robert Delage, Anargyros Xenocostas, Elena Liew, Kristjan Paulson, Tracy L. Stockley, Pierre Laneuville, Jeffrey H. Lipton, Suzanne Kamel-Reid, Brian Leber
Journal: Blood (2020)